Silexion Therapeutics Ltd. (SLXN) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Silexion Therapeutics Ltd. (SLXN) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.15 and trailing twelve-month earnings per share of $-20.31.
Compared to the Healthcare sector median P/E of 24.6x, SLXN trades at a 100% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, SLXN trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SLXN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SLXN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SLXN P/E vs Peers
RNA Medicines peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 127.9 | - | -405% | |
| $93B | 19.8Lowest | 3.13Best | +8% | |
| $32B | 36.7 | 8.67 | +171%Best | |
| $258B | 36.4 | 17.23 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SLXN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLXN — Frequently Asked Questions
Quick answers to the most common questions about buying SLXN stock.
What is SLXN's P/E ratio?
Silexion Therapeutics Ltd. (SLXN) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-20.31. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is SLXN stock overvalued or undervalued?
SLXN current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
Is SLXN stock expensive?
SLXN is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of N/A (N/A percentile of historical range).
What is SLXN's historical P/E range?
Over the past 5 years, SLXN's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -0.0x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does SLXN's P/E compare to the S&P 500?
SLXN current P/E: -0.0x. S&P 500 median P/E: 21.8x.
How does SLXN's valuation compare to Healthcare peers?
Silexion Therapeutics Ltd. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is SLXN's PEG ratio?
SLXN PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 97.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SLXN's earnings yield?
SLXN earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.